TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8804333
Drug: Episodic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Episodic infusion
Study: 15319760
Drug: Spinal Manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Manipulation Treatment (SMT)
Study: 6386484
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg etozolin (E)
Study: 6386484
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg furosemide (F)
Study: 29566437
Drug: Bimagrumab 10
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab 10 mg/kg
Study: 31397289
Drug: Bimagrumab 1
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab 1 mg/kg
Study: 31397289
Drug: Bimagrumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab (all doses)
Study: 27052266
Drug: QFT-G positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: QFT-G positive
Study: 27052266
Drug: LTBI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTBI treatment acceptance
Study: 17437728
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus thienopyridine
Study: 16416663
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg IM one hr before surgery (Group A)
Study: 16416663
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg into the surgical site (Group B)
Study: 16416663
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg IM one hr before surgery plus 50 mg into the surgical site (Group C)
Study: 9845561
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg twice daily for 1 week
Study: 1579623
Drug: Flunitrazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (2 mg)
Study: 2644129
Drug: High-dose Ara-C
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose Ara-C (3 g/m2 every 12 hours during 3 h of infusion)
Study: 2644129
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of standard maintenance treatment after consolidation with 4 courses of DAT (Daunorubicin + Ara-C + 6-Thioguanine)
Study: 2644129
Drug: High-dose Ara-C
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose Ara-C
Study: 301745
Drug: Diflunisal (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (acute single dose)
Study: 301745
Drug: Diflunisal (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (chronic multiple dose)
Study: 301745
Drug: Diflunisal (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (high dosage open study)
Study: 301745
Drug: Placebo (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (acute single dose)
Study: 301745
Drug: Placebo (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (chronic multiple dose)
Study: 301745
Drug: Placebo (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (high dosage open study)
Study: 29048511
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of the 2011 national guidelines on antibiotic prescriptions for ARTI, including local protocol implementation, education sessions, and feedback.
Study: 29048511
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of the 2011 national guidelines on antibiotic prescriptions for ARTI.
Study: 25728688
Drug: Internet-based guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based guided self-help intervention for PTSS, depression, and anxiety (10-week program based on cognitive behavior therapy)
Study: 23742144
Drug: Multiparametric score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiparametric score based on clinical status, echo Doppler variables, NT-proBNP, eGFR, and drug therapies.
Study: 21767341
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart twice‐daily
Study: 21767341
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin detemir once‐daily (twice if required)
Study: 15133775
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch, nicotine gum, or bupropion (33-50% of patients)
Study: 8437976
Drug: Theophylline short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline short-term infusion (420 mg theophylline)
Study: 8437976
Drug: Aminophylline short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminophylline short-term infusion (theophylline component 351.3 mg)
Study: 8437976
Drug: Theophylline and
Normalized name: theophylline and adrenergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline and aminophylline infusions
Study: 30854916
Drug: Ashwagandha extract
Normalized name: ashwagandha extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha extract (Shoden beads, 21 mg of withanolide glycosides per day)
Study: 30110693
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice daily with tramadol hydrochloride 50 mg twice daily (as required)
Study: 30110693
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride 50 mg twice daily for 6 weeks
Study: 24901856
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole, amoxicillin, and metronidazole)
Study: 24901856
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (omeprazole, tetracycline, metronidazole, and bismuth subcitrate)
Study: 24901856
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (both therapies combined)
Study: 17984816
Drug: Hib‐MenC‐TT vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib‐MenC‐TT vaccine
Study: 15691312
Drug: Second-line triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line triple therapy (7 days of omeprazole, amoxicillin and clarithromycin twice a day)
Study: 15691312
Drug: Second-line quadruple
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line quadruple therapy (7 days of omeprazole twice a day, plus tetracycline, metronidazole and bismuth subcitrate three times a day)
Study: 9706929
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids (lactated Ringer's solution 15 mL/kg within 15 min before spinal anesthesia)
Study: 9706929
Drug: Intraoperative application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative application of both sedatives and opioids (subgroup)
Study: 336818
Drug: S-carboxymethylcysteine (S-CMC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-carboxymethylcysteine (S-CMC; Mucodyne, Berk Pharmaceuticals)
Study: 9643620
Drug: Intravenous bambuterol
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bambuterol
Study: 9643620
Drug: Oral bambuterol
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bambuterol (single dose and repeated doses once daily for 7 days)
Study: 9643620
Drug: Generated terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generated terbutaline from oral bambuterol
Study: 9643620
Drug: Repeated oral
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated oral dosing of bambuterol
Study: 7945745
Drug: m-chlorophenylpiperazine (m-CPP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (m-CPP, 0.5 mg/kg p.o.)
Study: 7945745
Drug: L-tryptophan (L-TRP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (L-TRP, 100 mg/kg i.v.)
Study: 7945745
Drug: L-tryptophan (L-TRP)
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan (L-TRP)
Study: 8194933
Drug: Routine Treatment
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Treatment
Study: 3074860
Drug: Low-EE groups
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-EE groups (Education Only and Routine Treatment)
Study: 3074860
Drug: Education Only
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education Only and Routine Treatment groups
Study: 20581214
Drug: Oral celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral celecoxib from the evening before surgery until 48 hours after operation.
Study: 20404219
Drug: Amlodipine-atenolol combination
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine-atenolol combination
Study: 8701624
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg clindamycin
Study: 25025189
Drug: Hydrotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrotherapy treatment (three individual sessions each week for four weeks)
Study: 27220601
Drug: Rutin-containing cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rutin-containing cream
Study: 22658702
Drug: Methylphenidate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (1 mg/kg per day) for 90 days
Study: 15377651
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine (10 mg)
Study: 15377651
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine (10 mg) during hyperoxia
Study: 10918923
Drug: Indinavir liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir liquid (80 mL, 10 mg/mL)
Study: 10918923
Drug: Indinavir capsules
Normalized name: indinavir Oral Capsule
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir capsules (800 mg as two 400-mg capsules)
Study: 10918923
Drug: Indinavir liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir liquid and capsules
Study: 6600677
Drug: Sulindac 200
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 200 mg
Study: 6303553
Drug: Misonidazole 1.200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole 1.200 mg/m2 orally on each treatment day
Study: 27866658
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) with modulated electrohyperthermia (mEHT)
Study: 22650145
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection using cervical Jiaji (EX‐B 2), Fengchi (GB 20), Ashi points, etc. with medications including simple Chinese herbs (Danggui injection, etc.), compound Chinese herbs (compound Danggui injection, etc.), simple western medicine (vitamin B family, etc.), and Chinese herbs combined with western medicine (compound Danggui injection combined with vitamin B12, etc.)
Study: 20606481
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 200 mg orally thrice a day for 3 months
Study: 18001211
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg purified isoflavones administered in 2 divided doses of 40 mg for 12 weeks
Study: 11858482
Drug: s.c. melagatran
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. melagatran (1, 2 or 4 mg bid) for 2 days followed by oral ximelagatran (6, 12 or 24 mg bid) for 6-9 days
Study: 11858482
Drug: dalteparin 5000
Normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: dalteparin 5000 IU s.c. once daily for 8-11 days
Study: 11858482
Drug: s.c. melagatran
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. melagatran plus oral ximelagatran
Study: 7559370
Drug: Venlafaxine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (average dosage of approximately 350 mg/day during Weeks 2 to 4)
Study: 28786523
Drug: Sevelamer 3200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer 3200 mg
Study: 21959675
Drug: Tango dancing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tango dancing program (twice weekly for 12 months)
Study: 17324398
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg at weeks 0, 2, and 6, followed by maintenance therapy every 8 weeks
Study: 17324398
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg every 8 weeks
Study: 17324398
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg every 12 weeks
Study: 15466674
Drug: Comprehensive Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Cognitive Behavioral Therapy (CCBT)
Study: 15466674
Drug: CCBT/Fluoxetine (CCBT/FLU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCBT/Fluoxetine (CCBT/FLU)
Study: 15466674
Drug: Fluoxetine (FLU)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLU) and CCBT/FLU
Study: 15466674
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (CCBT/FLU)
Study: 11799259
Drug: Interferon-alpha (IFN-a)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-a) administered at a dosage of 3 million units three times weekly for 1 year
Study: 11799259
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IFN-a treatment)
Study: 2972597
Drug: Enoximone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (0.5 mg/kg as a bolus)
Study: 28628969
Drug: Remifentanil 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 100 μg/kg/min
Study: 22712560
Drug: Ultrasound pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound pre-treatment (1 MHz, 1 W/cm²)
Study: 22712560
Drug: Ultrasound simultaneous
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound simultaneous treatment (1 MHz, 1 W/cm²)
Study: 1727835
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (n = 166): Low-to-moderate-intensity endurance training, 40 minutes thrice weekly on a cycle ergometer, with training heart rate set at 70% of peak heart rate.
Study: 1727835
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control group (n = 81): Attended weekly group talks.
Study: 31498415
Drug: Topography-guided customized
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topography-guided customized ablation treatment (TCAT)
Study: 22918828
Drug: FDM-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDM-guided treatment
Study: 22918828
Drug: Conventional manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional manual therapy (MT)
Study: 18578221
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence interventions
Study: 8121459
Drug: c7E3 Fab
Normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: c7E3 Fab bolus and infusion
Study: 2763031
Drug: Dihydroergotamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine and heparin (DHE/Hep)
Study: 27434512
Drug: Robot-assisted group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted group activity with Paro, 30 minutes twice a week for 12 weeks
Study: 15876467
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon alpha‐2b (1.5 microg/kg) and ribavirin (400‐800 mg)
Study: 12828103
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (1g by continuous i.v. infusion starting 30 minutes before ERCP and continuing for 12 hours afterward)
Study: 1579221
Drug: Aspartame (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (40 mg/kg)
Study: 30064489
Drug: SODIS water
Approvals — FDA: no, EMA: no, PMDA: no
Description: SODIS water treatment intervention
Study: 18945637
Drug: Levosimendan 1
Normalized name: Levosimendán
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 1 mg once or twice daily
Study: 15716208
Drug: Control (non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-surgical treatment)
Study: 12429622
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 followed by paclitaxel 200 mg/m2 (1- or 3-hour infusion) for six to seven cycles.
Study: 12429622
Drug: Doxorubicin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin dose > 360 mg/m2
Study: 12429622
Drug: Doxorubicin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin dose 420 mg/m2
Study: 12429622
Drug: Doxorubicin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin dose < or = 360 mg/m2
Study: 10430734
Drug: Low and
Normalized name: ZINC OXIDE 88 mg in 1 mL TOPICAL LOTION [Ciele Glow and Protect]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low and high doses of budesonide with and without formoterol
Study: 10430734
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids prescribed for severe exacerbations
Study: 7748095
Drug: Intra‐operative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐operative management with endotracheal intubation, general anesthesia, nasogastric and urinary bladder catheters, position changes, rectal manometer, respiratory pressure module
Study: 7748095
Drug: Measurement techniques
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement techniques (bladder, rectal, gastric)
Study: 3579494
Drug: Scopolamine 0.25
Normalized name: scopolamine 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.25 mg
Study: 3579494
Drug: Scopolamine 0.1
Normalized name: scopolamine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.1 mg
Study: 31808183
Drug: Treatment protocol
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment protocol from 2008-2011 (all foals with pulmonary abscesses treated)
Study: 31808183
Drug: Treatment protocol
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment protocol from 2012-2016 (only foals with larger lesions treated)
Study: 31808183
Drug: Treatment protocol
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment protocol from 2008-2011
Study: 31808183
Drug: Treatment protocol
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment protocol from 2012-2016
Study: 29288881
Drug: Daily screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily screening including confirmatory chart reviews
Study: 16174597
Drug: Cefepime (Maxipime)
Normalized name: cefepime Injection [Maxipime]
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefepime (Maxipime) at 50 mg/kg intravenously twice daily
Study: 16174597
Drug: Sulbactam/Cefoperazone (Sulperazone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam/Cefoperazone (Sulperazone) at 50-100 mg/kg intravenously twice daily
Study: 12045314
Drug: Psychoeducational multiple-family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational multiple-family group treatment
Study: 9179369
Drug: Mistletoe lectin-I
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe lectin-I treatment
Study: 3129318
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC), 25 mg/day
Study: 3129318
Drug: Placebo, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 tablet/day
Study: 11120961
Drug: Telithromycin 400
Normalized name: telithromycin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin 400 mg
Study: 11120961
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg
Study: 11120961
Drug: Telithromycin 1600
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 1600 mg
Study: 30994826
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical treatment
Study: 31476881
Drug: IABP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IABP treatment
Study: 25102384
Drug: Activity-based therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity-based therapy (ABT) 9h/wk for 24 weeks
Study: 12011136
Drug: Adjuvant oophorectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant oophorectomy and tamoxifen (20 mg orally every day for 5 years)
Study: 10210974
Drug: HAART (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART (combination of zidovudine, lamivudine, and saquinavir)
Study: 2575453
Drug: Dextropropoxyphene napsylate
Normalized name: Dextropropoxyphene napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene napsylate with acetaminophen (DPN-A)